Table 2.

Distribution of patients with EOC, endometriosis, and ovarian benign cysts according to their positivity for CA125, HE4, and ROMA and diagnostic performances

PremenopausePostmenopause
EOC (N = 26)Cysts and endometriosis (N = 69)EOC (N = 87)Cysts (N = 96)
CA125a
 Positive24288217
 Negative241579
 Accuracy (95% CI)68.4 (58.1–77.6)88.0 (82.4–92.3)
 Sensitivity (95% CI)92.3 (74.9–99.1)94.3 (87.1–98.1)
 Specificity (95% CI)59.4 (46.9–71.1)82.3 (73.2–89.3)
HE4b
 Positive224681
 Negative4651995
 Accuracy (95% CI)91.6 (84.1–96.3)89.1 (83.6–93.2)
 Sensitivity (95% CI)84.6 (65.1–95.6)78.2 (68.0–86.3)
 Specificity (95% CI)94.2 (85.8–98.4)99.0 (94.3–100.0)
ROMAc
 Positive2248115
 Negative1356681
 Accuracy (95% CI)82.1 (72.9–89.2)88.5 (83.0–92.8)
 Sensitivity (95% CI)84.6 (65.1–95.6)93.1 (85.6–97.4)
 Specificity (95% CI)81.2 (69.9–89.6)84.4 (75.5–91.0)

NOTE: “Positive” indicates values above the cutoff and “negative” indicates values below the cutoff.

  • aFor CA125, cutoff value was 35 U/mL.

  • bFor HE4, cutoff values were ≤70 pmol/L for premenopausal state and ≤140 pmol/L in menopausal state.

  • cFor ROMA, cutoff values were ≤7.4% for premenopausal state and ≤25.3% menopausal state.